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SUMMARY
Aqueous misdirection syndrome is a rare, incompletely 
understood, sight- threatening eye condition that is 
difficult to diagnose and treat. We present a case of 
simultaneous bilateral aqueous misdirection following 
the administration of certolizumab in a 41- year- old 
women with rheumatoid arthritis and no known risk 
factors. To our knowledge, aqueous misdirection has 
not previously been associated with the use of tumour 
necrosis factor- alpha inhibitors.
BACKGROUND
Aqueous misdirection syndrome (AMS), also known 
as malignant glaucoma, is a sight- threatening 
condition associated with a uniform shallowing 
of the anterior chamber and normal or elevated 
intraocular pressure (IOP).1 The exact mechanism 
is incompletely understood, but thought to be 
related to a redirection of aqueous humour into the 
vitreous due to anterior rotation of the ciliary body 
with consequent ciliolenticular and/or vitreous 
block. AMS can occur spontaneously, but is most 
frequently seen in the context of cataract or glau-
coma surgery.1 Other risk factors include hyperopia 
and previous angle- closure. The diagnosis is made 
by the observation of axial flattening of the anterior 
chamber despite a patent iridotomy, in the pres-
ence of elevated or sometimes normal IOP. Miotics 
can worsen AMS, while cycloplegics may improve 
the condition. Most patients require neodymium- 
doped yttrium aluminum garnet (Nd:YAG) laser 
anterior hyaloidotomy with posterior capsulotomy 
if pseudophakic or phacoemulsification combined 
with pars plana vitrectomy if phakic.1 Certolizumab 
pegol is a pegylated antigen- binding fragment (Fab) 
of humanised tumour necrosis factor- alpha (TNF-
⍺) antibody,2 used for the treatment of rheumatoid 
arthritis, ankylosing spondylitis, Crohn’s disease 
and other autoimmune diseases.3 Herein, we report 
an unusual case of simultaneous bilateral AMS asso-
ciated with certolizumab therapy for rheumatoid 
arthritis.
CASE PRESENTATION
A 41- year- old women, with rheumatoid arthritis 
and no history of eye disease or surgery, was 
admitted to the neurology department with acute 
blurred vision and headache of 3–4 weeks duration. 
A transient ischaemic attack was first suspected, but 
neurological workup and imaging were normal. 
During the past 4 years, she had been treated with 
prednisolone and various disease- modifying anti-
rheumatic drugs (sulfasalazine, infliximab, etaner-
cept, adalimumab) without satisfactory response. 
Five weeks prior to presentation, she had started 
on 400 mg certolizumab pegol injections every 
2 weeks. Apart from oral prednisolone, 15 mg/
day, she had not been using any other drugs during 
the last month before starting certolizumab. An 
erythematous rash developed at the injection site 
9 days after the first certolizumab injection. After 
the second injection, 2 weeks later, she was there-
fore given a single dose of oral cetirizine 10 mg. 
The third and last certolizumab injection was 6 days 
prior to presentation, given at half dose (200 mg) 
together with cetirizine 10 mg/day for 3 days to 
reduce the symptoms and appearance of the local 
skin reaction. Her uncorrected visual acuity (VA) 
was 20/200 in both eyes (OU). Despite a history 
of emmetropia, a best- corrected VA of 20/30 OU 
was achieved with a spherical equivalent correction 
(SEC) of −6 and −6.25 dioptres (D) in the right 
eye (OD) and left eye (OS), respectively. Slit- lamp 
examination revealed a uniform shallowing of the 
anterior chambers, with anterior displacement of 
the lens–iris complex and no signs of choroidal 
effusion (figure 1). Gonioscopy showed almost 
completely occluded angles, and IOP was 36 mm 
Hg bilaterally. Acute angle- closure glaucoma 
was suspected, and she was given maximal IOP- 
lowering medication and bilateral Nd:YAG laser 
iridotomy aided by pilocarpine 2%. The following 
morning, IOP was 14 mm Hg OU, but the anterior 
chambers were still very shallow, and her refractive 
error had increased to −7.25 and −8.00 D. Optical 
biometry revealed shallow anterior chamber depths 
of 1.16 mm and 1.43 mm, normal lens thicknesses 
of 4.39 mm and 4.43 mm and normal axial lengths 
of 23.57 and 23.47 mm in OD and OS, respec-
tively. B- scan ultrasonography was performed to 
exclude choroidal effusion. Based on the clinical 
course and ancillary findings, a diagnosis of bilat-
eral AMS was made. Bilateral Nd:YAG laser ante-
rior hyaloidotomy was performed followed by 
topical cyclopentolate 0.5%, dexamethasone 0.1%, 
dorzolamide/timolol and oral prednisolone. Imme-
diately after the hyaloidotomy, a significant deep-
ening of the anterior chambers was observed. Four 
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noted, and the IOP was 13 mm Hg and 12 mm Hg in OD and 
OS, respectively (figure 1).
OUTCOME AND FOLLOW-UP
After 4 days, her VA was 20/20 OU with a SEC of +0.2 D OD 
and +0.0 D OS. Certolizumab was discontinued due to the 
high probability of being the causative agent. Within 4 weeks, 
all topical medications were withdrawn, and the IOP remained 
within the normal range. Four months follow- up revealed normal 
visual fields, normal IOP, normal peripapillary retinal nerve 
fibre layers by spectral domain optical coherence tomography, 
stable emmetropia and normal visual function without any other 
complaints. Her rheumatoid arthritis was subsequently treated 
with oral prednisolone 5–20 mg/day, adjusted according to clin-
ical response.
DISCUSSION
Spontaneous bilateral AMS is a rare event,4 and only six cases 
are reported in the literature.5–10 A limitation of our study is 
the lack of ultrasound biomicroscopy (UBM) due to equipment 
malfunction. UBM may have helped to identify the status of the 
ciliary body and processes as well as possible ciliary body effu-
sion that can precipitate AMS.1 Pupillary block glaucoma has 
been associated with certain antihistamines owing to their weak 
anticholinergic activity.11 Cetirizine, however, has a negligible 
anticholinergic activity, and we have not found any reports in 
the literature on an association between cetirizine medication 
and pupillary block or angle- closure. In our patient, there is 
substantial evidence against a pupillary block, and for an AMS 
mechanism, including a lack of resolution after iridotomy, a 
uniform shallowing of the anterior chambers and an increasing 
myopic shift following miotics. A possible molecular explana-
tion for the association between certolizumab and AMS could 
be an inhibition of TNF-α-induced expression of the vasoac-
tive and smooth muscle- contracting peptide endothelin-1 in the 
ciliary body,12 13 which may have altered the normal dynamics 
of aqueous humour and thereby led to its misdirection. To the 
best of our knowledge, this is the first report of AMS following 
the administration of a TNF-α inhibitor. Although our report 
is based on a single case and other causes cannot be completely 
ruled out, the time course and the lack of any predisposing risk 
factors suggest that the bilateral AMS in our patient was induced 
by certolizumab. Patients with known risk factors such as axial 
hyperopia and a history of primary angle- closure may need to 
be followed more closely with UBM after starting certolizumab.
Learning points
 ► Aqueous misdirection syndrome (AMS) is a diagnostic and 
therapeutic challenge, where immediate recognition and 
treatment can improve the outcome.
 ► AMS may first present to non- ophthalmologists and 
masquerade as an acute neurological condition.
 ► An insidious increase in intraocular pressure, a shallow 
anterior chamber both centrally and peripherally, and an 
increasing myopic shift are signs to look out for.
 ► Bilateral AMS rarely occurs spontaneously in patients without 
any risk factors.
 ► Cycloplegics and laser anterior hyaloidotomy may reverse the 
condition.
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Figure 1 Scheimpflug images and slit- lamp photographs of 
the anterior segment. Clinical images demonstrating the anterior 
displacement of the lens- iris diaphragm and narrow chamber angle 
in both eyes prior to laser anterior hyaloidotomy (top row). One day 
after treatment, there is a marked deepening of the anterior chambers 
(bottom row). The Scheimpflug images were acquired using Pentacam 
(Oculus, Lynnwood, Washington, USA), and the numbers in red indicate 
the automatically calculated anterior chamber angle width. OD: right 
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